Legal & General Group
KNTE

Legal & General Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Legal & General Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,831
Closed -$17.7K – 3558
2023
Q1 		$17.7K Hold
2,831
– – ﹤0.01% 3098
2022
Q4 		$17.2K Hold
2,831
– – ﹤0.01% 3186
2022
Q3 		$34K Buy
2,831
+345
+14% +$4.51K ﹤0.01% 3069
2022
Q2 		$31K Sell
2,486
-1,739
-41% -$16.2K ﹤0.01% 3109
2022
Q1 		$48K Hold
4,225
– – ﹤0.01% 3012
2021
Q4 		$75K Hold
4,225
– – ﹤0.01% 2964
2021
Q3 		$97K Buy
4,225
+3,102
+276% +$67.5K ﹤0.01% 2856
2021
Q2 		$26K Sell
1,123
-247
-18% -$6.28K ﹤0.01% 3197
2021
Q1 		$42K Buy
+1,370
New +$47.7K ﹤0.01% 2876

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's KNTE Position: Q2 2023 in Review

Legal & General Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 2,831 shares — an estimated $17.7K sold.

Legal & General Group first reported a position in KNTE in Q1 2021 and held it in 9 quarters. The position peaked at $97K in Q3 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Legal & General Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 2,831 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $17.7K.
  • Legal & General Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Legal & General Group's Kinnate Biopharma Inc. Common Stock position peaked at $97K in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.